IRIS
COSTANTINO, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 508
NA - Nord America 476
AS - Asia 80
SA - Sud America 1
Totale 1.065
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 475
SE - Svezia 165
IE - Irlanda 145
CN - Cina 79
GB - Regno Unito 49
DE - Germania 48
UA - Ucraina 32
FR - Francia 29
IT - Italia 21
FI - Finlandia 16
BE - Belgio 2
CA - Canada 1
CL - Cile 1
RO - Romania 1
UZ - Uzbekistan 1
Totale 1.065
Salva come PNG Salva come JPEG
Città #
Dublin 145
Chandler 124
Jacksonville 68
Nyköping 68
Lancaster 40
Dearborn 39
Beijing 33
Ashburn 31
Bremen 20
Princeton 20
Cambridge 17
Boardman 15
Des Moines 13
Medford 13
Shenyang 12
Wilmington 8
Jinan 5
Messina 5
Ann Arbor 4
Haikou 4
Hebei 4
San Mateo 4
Tianjin 4
Washington 4
Woodbridge 4
Vittoria 3
Brussels 2
Campobasso 2
Changsha 2
Lanzhou 2
Ningbo 2
Novara 2
Taizhou 2
Zhengzhou 2
Albairate 1
Bari 1
Boves 1
Brasov 1
Caserta 1
Ficarra 1
Guangzhou 1
Hefei 1
Kunming 1
London 1
Nanjing 1
Nürnberg 1
Seattle 1
Shanghai 1
Trecastagni 1
Viersen 1
Totale 739
Salva come PNG Salva come JPEG
Nome #
Urinary neutrophil gelatinase-associated lipocalin (uNGAL) levels in patients with Crohn’s disease undergoing treatment with infliximab. 72
Response evaluation and safety of thiopurines in the treatment of inflammatory bowel diseases (IBD): safety and response evaluation. 69
Azathioprine/6-Mercaptopurine in the treatment of inflammatory bowel disease (IBD)- A single centre experience. 66
Prevention of post-surgical recurrence with adalimumab in a patient with complicated Crohn's disease. 63
Ileal tight junction (TJ) alterations associated with experimental colitis – a time course. 60
Fecal calprotectin correlates with intestinal permeabilità (IP) in patients with Crohn’s disease. 59
Thiopurine treatment in inflammatory bowel disease: response predictors, safety and withdrawal in follow-up. 59
Infliximab normalizes intestinal permeability in the short-term but not fecal calprotectin in Crohn’s disease 57
Thalidomide for refractory bleeding small intestinal Crohn’s disease– a case report 57
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 56
Therapy-related adverse events in Crohn’s disease (CD) – a comparison between thiopurines, infliximab and combined therapy. 54
Thiopurines in the treatment of inflammatory bowel diseases – a single centre experience. 53
Clinical practice in the management of ulcerative colitis - an Italian survey 52
Treatment of life threatening type I refractory celiac disease with long term infliximab 51
Predicting response to thiopurines – a single centre experience. 49
Infliximab and etanercept are equally effective in reducing enterocyte apoptosis in experimental colitis. 48
Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 37
Pan-digestive tract colonization by CMV in Common Variable Immunodeficiency. 36
null 28
Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy 24
null 21
Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment. 13
Totale 1.084
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.758
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.758
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192 0 0 0 0 0 0 0 0 0 0 2 0
2019/2020160 16 3 0 3 0 33 32 29 1 22 21 0
2020/2021155 17 1 34 14 9 25 4 11 0 14 14 12
2021/2022137 0 17 0 6 4 0 7 7 0 46 11 39
2022/2023433 33 45 23 31 48 45 3 16 176 2 8 3
2023/202482 7 15 9 17 15 15 1 3 0 0 0 0
Totale 1.084